Pentoxifylline Treatment in Severe Acute Pancreatitis: A Pilot, Double-Blind, Placebo-Controlled, Randomized Trial.

In acute pancreatitis (AP) tumor necrosis factor-α mediates multi-organ failure; in animal models its blockade with pentoxifylline ameliorates AP. The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested in a double-blinded, randomized, control trial. Twenty-eight patients with pSAP were randomized within 72 hours of diagnosis to pentoxifylline or placebo. Baseline characteristics were similar in both groups. The pentoxifylline group had fewer intensive care unit admissions and shorter intensive care unit and hospital stays of longer than 4 days (all P < .05). Patients receiving pentoxifylline had no adverse effects. Pentoxifylline within 72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy. ClinicalTrials.gov number: NCT01292005.

[1]  A. Coelho,et al.  Effects of intravenous administration of pentoxifylline in pancreatic ischaemia-reperfusion injury. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[2]  Seth D. Crockett,et al.  Burden of gastrointestinal disease in the United States: 2012 update. , 2012, Gastroenterology.

[3]  M. Machado,et al.  Is there a therapeutic window for pentoxifylline after the onset of acute pancreatitis? , 2012, Acta cirurgica brasileira.

[4]  A. Cueto-Manzano,et al.  Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  D. Christodoulou,et al.  A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. , 2007, Gastrointestinal endoscopy.

[6]  E. Mazzon,et al.  ROLE OF TUMOR NECROSIS FACTOR-&agr; IN ACUTE PANCREATITIS: FROM BIOLOGICAL BASIS TO CLINICAL EVIDENCE , 2007, Shock.

[7]  J. Sastre,et al.  Effect of Simultaneous Inhibition of TNF-α Production and Xanthine Oxidase in Experimental Acute Pancreatitis: The Role of Mitogen Activated Protein Kinases , 2004, Annals of surgery.

[8]  H. Çelik,et al.  Infliximab:: A New Therapeutic Agent in Acute Pancreatitis? , 2004, Pancreas.

[9]  T. Reynolds,et al.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[10]  M. Franz,et al.  Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. , 1996, Surgery.

[11]  N. Németh,et al.  Effects of various drugs (flunixin, pentoxifylline, enoxaparin) modulating micro-rheological changes in cerulein-induced acute pancreatitis in the rat. , 2014, Clinical hemorheology and microcirculation.

[12]  H. Gooszen,et al.  Early angiopoietin-2 levels after onset predict the advent of severe pancreatitis, multiple organ failure, and infectious complications in patients with acute pancreatitis. , 2014, Journal of the American College of Surgeons.

[13]  M. Kotb,et al.  Inhibition of TNFα improves survival in an experimental model of acute pancreatitis , 1996 .

[14]  V. Trusov,et al.  [Trial of the combined use of trental and solcoseryl in treating patients with chronic pancreatitis]. , 1988, Terapevticheskii arkhiv.